Neurocrine Biosciences Announces Topline Data from Phase IIb T-Force GOLD Study Demonstrating Valbenazine Did Not Meet Primary Endpoint in Pediatric Patients with Tourette Syndrome
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Neurocrine Bio. (NBIX) PT Lowered to $102 at H.C. Wainwright
December 13, 2018 11:09 AM ESTH.C. Wainwright analyst Andrew Fein lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $102.00 (from $162.00) while maintaining a Buy rating.
... MoreNeurocrine Bio. (NBIX) PT Lowered to $105 at Oppenheimer
December 13, 2018 9:30 AM ESTOppenheimer analyst Jay Olson lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $105.00 (from $140.00) while maintaining a Outperform rating.
Olson commented, "T-Force-GOLD missed the primary endpoint, sending NBIX shares down 14% on 12/12 (vs. NBI +1.3% and S&P 500 +0.5%) on the loss of this important... More
Neurocrine Bio. (NBIX) PT Lowered to $96 at Baird, Removed from 'Fresh Pick' List
December 12, 2018 12:16 PM ESTBaird analyst Brian Skorney lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $96.00 (from $131.00) while maintaining an Outperform rating and removed the Fresh Pick designation on Tourette failure.
As a result, the firm is reducing their peak sales estimate for... More
Neurocrine Bio. (NBIX) PT Lowered to $104 at Needham & Company
December 12, 2018 10:48 AM ESTNeedham & Company analyst Alan Carr lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $104.00 (from $125.00) while maintaining a Buy rating.
Carr commented, "Neurocrine announced that the Phase 2b/3 T-Force GOLD trial of Ingrezza in Tourette Syndrome did not meet primary... More
Neurocrine Biosciences (NBIX) to Resume Trading at 8 am ET
December 12, 2018 7:34 AM ESTNeurocrine Biosciences (NASDAQ: NBIX) to Resume Trading at 8 am ET
... More